Form D · Biotechnology
Zalicus Inc.
Cambridge, MA · CIK 0001135906
Offering snapshot reported Dec 22, 2010 · SEC filing
- Reported sold
- $0 Indefinite offering
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 22, 2010 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 22, 2010 | Initial | $0 | No comparison | 1 | SEC filing |
| Oct 17, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-152398
Issued a warrant to purchase common stock that is exercisable in connection with a Loan and Security Agreement. See Form 8-K filed with the SEC on December 22, 2010 for additional details.
Source: Form D, filed Dec 22, 2010. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jason F. Cole | Executive |
| Mark H.N. Corrigan | Director, Executive |
| Sally W. Crawford | Director |
| Todd Foley | Director |
| Christopher C. Gallen | Executive |
| Frank Haydu | Director |
| William Hunter | Director |
| Michael G. Kauffman | Director |
| W. James O'shea | Director |
| Justin A. Renz | Executive |
| Hartley T. Richardson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
245 First Street 3 Rd Floor
Cambridge, MA, 02142
Cambridge, MA, 02142